Cometriq (Cabozantinib S-Malate) Patent Expiration, LOE Window & CMS Spending

Cometriq (Cabozantinib S-Malate) by Exelixis: FDA Orange Book core substance LOE 2030-10-08 (last listed 2032-02-10), 1 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorExelixis
FDA Application & PathwayN203756 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-10-08
Last Listed Patent or Exclusivity Date2032-02-10
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$4.0M
2024 Medicare Part D Spend$3.3M
2024 Medicaid Spend$696K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.